Skip to content

Study · In vitro (cells) · 2000

3 results

IGF-I stimulates chemotaxis of human neuroblasts. Involvement of type 1 IGF receptor, IGF binding proteins, phosphatidylinositol-3 kinase pathway and plasmin system.

Puglianiello A, Germani D, Rossi P, Cianfarani S

The Journal of endocrinology1 Apr 2000Cited by 37 (Europe PMC)

PMID10750042 (opens in a new tab)DOI10.1677/joe.0.1650123 (opens in a new tab)PepBankPUB-10750042
Source linkPubMedAsk about this study
Jump to 3 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study3

2 results from studies that gave the peptide. No result from this study comes from people.

  1. 01LabIn vitro (cells)Activity measurement

    Des(1‑3)IGF-I stimulated SH-SY5Y neuroblast chemotaxis in a dose-dependent manner.

    In plain wordsIn cells, des(1‑3)IGF-I increased neuroblast movement toward a chemical signal as dose increased.

    Peptide
    IGF-1 DES (des(1-3)IGF-I)
    Outcome
    IncreaseChemotaxis
    Study

    humann: not reported in source

    SH-SY5Y neuroblastoma cells
    Outcome group
    Receptor activity and mechanism · Nervous system and cognition
    Studied dose
    Dose not stated

    Source sentences

    Summary
    IGF-I and des(1-3)IGF-I stimulated neuroblast chemotaxis in a dose-dependent manner.
    2 context sentences
    Summary · context
    SH-SY5Y human neuroblastoma cells express IGF receptors, IGFs and IGF binding proteins (IGFBPs), and provide a model for studying the role of the IGF system in human neuronal development.
    Summary · context
    We investigated the effect of IGF-I and des(1-3)IGF-I on the motility of SH-SY5Y cells by a cell migration assay based on the assessment of the number of cells which migrated across 8 microm pore size membranes and around an agarose drop.
  2. 02LabIn vitro (cells)Activity measurement

    Des(1‑3)IGF-I increased SH-SY5Y cell motility by 90% relative to control conditions after 24 h.

    In plain wordsIn cells, des(1‑3)IGF-I increased movement by 90% compared with control conditions after 24 hours.

    Peptide
    IGF-1 DES (des(1-3)IGF-I)
    Outcome
    IncreaseCell motility
    Study

    humann: not reported in source

    SH-SY5Y neuroblastoma cells
    Comparator
    control conditions
    Outcome group
    Receptor activity and mechanism · Nervous system and cognition
    Studied dose
    Dose not stated · 24 hAs given in this study (human).

    Measurements

    Motility increase
    90%
    relative to control conditions

    Source sentences

    Summary
    Treatment of cells with these agents for 24 h resulted in a significant increase (IGF-I by 70% and des(1-3)IGF-I by 90%; P<0. 0001) in cell motility relative to control conditions.
    2 context sentences
    Summary · context
    SH-SY5Y human neuroblastoma cells express IGF receptors, IGFs and IGF binding proteins (IGFBPs), and provide a model for studying the role of the IGF system in human neuronal development.
    Summary · context
    We investigated the effect of IGF-I and des(1-3)IGF-I on the motility of SH-SY5Y cells by a cell migration assay based on the assessment of the number of cells which migrated across 8 microm pore size membranes and around an agarose drop.

Studies that did not test the peptide alone1

In this study, IGF-1 DES (des(1-3)IGF-I) was a lab tool or a carrier, part of a mix, or the subject of a lab method. These results are not evidence about taking IGF-1 DES (des(1-3)IGF-I).

  1. 03LabNot a test of IGF-1 DES (des(1-3)IGF-I) aloneIn vitro (cells)Mechanism

    Type 1 IGF receptor antibody reduced des(1‑3)IGF-I-induced SH-SY5Y cell motility by 70%.

    In plain wordsIn cells, a receptor-blocking antibody reduced movement induced by des(1‑3)IGF-I compared with peptide alone.

    Peptide
    IGF-1 DES (des(1-3)IGF-I)
    Outcome
    DecreaseReceptor antibody inhibition of motility
    Study

    humann: not reported in source

    SH-SY5Y neuroblastoma cells
    Comparator
    des(1-3)IGF-I alone
    Outcome group
    Receptor activity and mechanism · Nervous system and cognition

    Measurements

    Cell motility reduction
    70%
    type 1 IGF receptor antibody versus des(1-3)IGF-I alone

    Source sentences

    Summary
    Addition of monoclonal antibody against type 1 IGF receptor (alpha-IR3), significantly (P<0.05) reduced the cell motility induced by IGF-I (by 30%) and des(1-3)IGF-I (by 70%).
    2 context sentences
    Summary · context
    SH-SY5Y human neuroblastoma cells express IGF receptors, IGFs and IGF binding proteins (IGFBPs), and provide a model for studying the role of the IGF system in human neuronal development.
    Summary · context
    We investigated the effect of IGF-I and des(1-3)IGF-I on the motility of SH-SY5Y cells by a cell migration assay based on the assessment of the number of cells which migrated across 8 microm pore size membranes and around an agarose drop.

    In this study, IGF-1 DES (des(1-3)IGF-I) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking IGF-1 DES (des(1-3)IGF-I).

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 3Current

    21 Oct 2026, 15:58 UTC

    Study results updated

  2. Version 2

    21 Oct 2026, 13:52 UTC

    Study data updated · source update from Europe PMC

  3. Version 1

    21 Oct 2026, 12:50 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

Publication types

PepBank is a research reference. Talk to a doctor before you use any peptide.